EX-99.1 2 ex991-interimfsmarch312022.htm EX-99.1 2022 FIRST QUARTER INTERIM FINANCIAL STATEMENTS Document





















Condensed Interim Consolidated Financial Statements
(unaudited)

Oncolytics Biotech® Inc.
March 31, 2022 and 2021



ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)
(in Canadian dollars, except share amounts)
As at March 31,
2022		December 31,
2021
Assets  
Current assets  
Cash and cash equivalents (note 4)$39,483,022 $41,262,044 
Other receivables (note 8)102,217 866,055 
Prepaid expenses3,950,332 2,775,800 
Total current assets43,535,571 44,903,899 
Property and equipment403,153 392,041 
Right-of-use assets507,556 584,251 
Total assets$44,446,280 $45,880,191 
Liabilities And Shareholders’ Equity  
Current Liabilities  
Accounts payable and accrued liabilities$2,048,476 $1,987,870 
Other liabilities (note 8)— 352,279 
Lease liabilities (note 8)307,480 293,672 
Warrant derivative (note 5, 10)68,231 56,017 
Total current liabilities2,424,187 2,689,838 
Contract liability 6,730,287 6,730,287 
Lease liabilities (note 8)276,640 361,081 
Total liabilities9,431,114 9,781,206 
Commitments and contingencies (note 8)
Shareholders’ equity   
Share capital (note 5)
  Authorized: unlimited
  Issued: March 31, 2022 – 57,501,688
  December 31, 2021 – 55,043,789
396,504,249 391,348,183 
Warrants (note 5)3,617,570 3,617,570 
Contributed surplus (note 6)34,746,749 34,161,103 
Accumulated other comprehensive income340,728 387,738 
Accumulated deficit(400,194,130)(393,415,609)
Total shareholders’ equity 35,015,166 36,098,985 
Total liabilities and shareholder's equity$44,446,280 $45,880,191 
See accompanying notes
2





ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)
(in Canadian dollars, except share amounts)
For the three months ended March 31,20222021
Expenses  
   Research and development (note 6, 12, 13)$3,707,996 $2,759,014 
   Operating (note 6, 12, 13)2,602,090 3,141,890 
Loss before the following(6,310,086)(5,900,904)
   Change in fair value of warrant derivative (note 10)(13,019)(164,780)
 Foreign exchange loss(474,120)(390,554)
   Interest income, net18,704 21,493 
Net loss(6,778,521)(6,434,745)
Other comprehensive loss items that may be reclassified to net loss
  Translation adjustment(47,010)(40,312)
Net comprehensive loss$(6,825,531)$(6,475,057)
Basic and diluted loss per common share (note 7)$(0.12)$(0.13)
Weighted average number of shares (basic and diluted) (note 7)56,576,462 49,666,585 
See accompanying notes


3



ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)
(in Canadian dollars)
Share CapitalWarrantsContributed SurplusAccumulated Other Comprehensive IncomeAccumulated DeficitTotal
As at December 31, 2020$356,824,172 $3,617,570 $31,022,356 $400,225 $(367,111,330)$24,752,993 
Net loss and other comprehensive loss— — — (40,312)(6,434,745)(6,475,057)
Issued pursuant to stock option plan (note 5, 6)302,908 — (113,558)— — 189,350 
Issued pursuant to incentive share award plan (note 5, 6)292,039 — (292,039)— — — 
Issued pursuant to "At the Market" Agreement (note 5)25,831,909 — — — — 25,831,909 
Issued pursuant to warrant derivative exercised (note 5)686,616 — — — — 686,616 
Share-based compensation (note 6)— — 658,076 — — 658,076 
Share issue costs (note 5)(974,247)— — — — (974,247)
As at March 31, 2021$382,963,397 $3,617,570 $31,274,835 $359,913 $(373,546,075)$44,669,640 
As at December 31, 2021$391,348,183 $3,617,570 $34,161,103 $387,738 $(393,415,609)$36,098,985 
Net loss and other comprehensive income— — — (47,010)(6,778,521)(6,825,531)
Issued pursuant to stock option plan (note 5, 6)19,570 — (7,487)— — 12,083 
Issued pursuant to incentive share award plan (note 5, 6)45,848 — (45,848)— — — 
Issued pursuant to "At the Market" Agreement (note 5)5,267,058 — — — — 5,267,058 
Share-based compensation (note 6)— — 638,981 — — 638,981 
Share issue costs (note 5)(176,410)— — — — (176,410)
As at March 31, 2022$396,504,249 $3,617,570 $34,746,749 $340,728 $(400,194,130)$35,015,166 
See accompanying notes

4





ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in Canadian dollars)
For the three months ended March 31,20222021
Operating Activities  
Net loss for the period$(6,778,521)$(6,434,745)
Depreciation - property and equipment (note 12)23,952 20,550 
Depreciation - right-of-use-assets (note 12)73,612 86,184 
Share-based compensation (note 6, 12, 13)638,981 658,076 
Interest expense on lease liabilities23,774 13,809 
Unrealized foreign exchange loss 409,863 519,368 
Change in fair value of warrant derivative (note 10)13,019 164,780 
Net change in non-cash working capital (note 11)(656,805)(596,479)
Cash used in operating activities(6,252,125)(5,568,457)
Investing Activities  
Acquisition of property and equipment(35,521)— 
Cash used in investing activities(35,521)— 
Financing Activities  
Proceeds from exercise of stock options (note 6)12,083 189,350 
Proceeds from exercise of warrant derivative (note 5)— 230,946 
Proceeds from "At the Market" equity distribution agreement (note 5)5,090,648 24,857,662 
Payment of lease liabilities(88,836)(111,673)
Cash provided by financing activities5,013,895 25,166,285 
(Decrease) increase in cash(1,273,751)19,597,828 
Cash and cash equivalents, beginning of period41,262,044 31,219,574 
Impact of foreign exchange on cash and cash equivalents(505,271)(455,240)
Cash and cash equivalents, end of period$39,483,022 $50,362,162 
See accompanying notes

5

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
Note 1: Incorporation and Nature of Operations

Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc.

Our condensed interim consolidated financial statements for the period ended March 31, 2022, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on May 4, 2022. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11th Avenue SW, Calgary, Alberta, Canada.

We are a development-stage biopharmaceutical company that focuses on the discovery and development of immunotherapeutic products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is an intravenously delivered immunotherapeutic agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.

The full extent to which the coronavirus infectious disease 2019 ("COVID-19") pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our condensed interim consolidated financial statements as of and for the period ended March 31, 2022, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.

Note 2: Basis of Financial Statement Presentation

Our condensed interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at March 31, 2022 and are presented in Canadian dollars, our functional currency.
Our accounts are prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.
These condensed interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 Interim Financial Reporting. The notes presented in these condensed interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended December 31, 2021. We have consistently applied the same accounting policies for all periods presented in these condensed interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended December 31, 2021.

6

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
Note 3: Significant Accounting Policies

Accounting Standards and Interpretations Issued but Not Yet Effective

IAS 1 Presentation of Financial Statements
In February 2021, the IASB issued amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors
In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

IAS 12 Income Taxes
In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.

Note 4: Cash Equivalents
 
Cash equivalents consist of interest bearing deposits with our bank totaling $34,402,959 (December 31, 2021 – $39,901,509).  The current annual interest rate earned on these deposits is 0.46% (December 31, 2021 – 0.45%).

7

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
Note 5: Share Capital
Authorized:
Unlimited number of no par value common shares
Shares
NumberAmount
As at December 31, 202046,166,980 $356,824,172 
Issued pursuant to stock option plan123,159 381,771 
Issued pursuant to incentive share award plan150,899 543,833 
Issued pursuant to "At the Market" (ATM) equity distribution agreement(a)(c)
8,401,029 34,168,071 
Issued pursuant to warrant derivative exercised(b)
201,722 686,616 
Share issue costs— (1,256,280)
As at December 31, 202155,043,789 $391,348,183 
Issued pursuant to stock option plan8,333 19,570 
Issued pursuant to incentive share award plan18,266 45,848 
Issued pursuant to "At the Market" (ATM) equity distribution agreement(c)
2,431,300 5,267,058 
Share issue costs— (176,410)
As at March 31, 202257,501,688 $396,504,249 
(a)On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021, and no shares were issued during the three months ended March 31, 2022. During the three months ended March 31, 2021, we sold 5,685,097 common shares for gross proceeds of US$18,503,188 at an average price of US$3.25. We received, net of commissions of US$555,096, proceeds of US$17,948,092. In total, we incurred share issue costs (including commissions) of $707,421.

(b)On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability. Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. No warrants were exercised during the three months ended March 31, 2022. During the three months ended March 31, 2021, our share capital included fair value of $455,670 in addition to gross proceeds of US$181,550 for the 201,722 warrants that were exercised.

(c)On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. During the three months ended March 31, 2022, we sold 2,431,300 (March 31, 2021 - 628,122) common shares for gross proceeds of US$4,174,022 (March 31, 2021 - US$1,937,063) at an average price of US$1.72 (March 31, 2021 - US$3.08). We received, net of commissions of US$125,221 (March 31, 2021 - US$58,112), proceeds of US$4,048,801 (March 31, 2021 - US$1,878,951). In total, we incurred share issue costs (including commissions) of $176,410 (March 31, 2021 - $266,826).
Equity Warrants
On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity.

8

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
The following table summarizes our outstanding equity warrants:
Number(1)
Amount
As at December 31, 202116,443,500 $3,617,570 
As at March 31, 202216,443,500 $3,617,570 
(1) Exercisable into 1,730,894 common shares.

Note 6: Share-Based Compensation
Stock Option Plan
We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at March 31:
20222021
Stock OptionsWeighted Average Exercise Price
$		Stock OptionsWeighted Average Exercise Price
$
Outstanding, beginning of the period5,334,420 3.533,764,055 4.08
Granted50,000 1.701,087,500 3.40
Forfeited(27,699)3.57— —
Expired (247,559)7.41— —
Exercised(8,333)1.45(88,492)2.14
Outstanding, end of the period5,100,829 3.334,763,063 3.96
Exercisable, end of the period3,359,589 3.522,156,834 5.03

The following table summarizes information about the stock options outstanding and exercisable at March 31, 2022:
Range of Exercise PricesNumber OutstandingWeighted Average Remaining Contractual Life (years)
Weighted Average Exercise Price
$
Number Exercisable
Weighted Average Exercise Price
$
$0.54 - $1.79759,998 1.961.41709,998 1.39
$1.80 - $3.011,011,942 3.622.36516,542 2.46
$3.02 - $3.902,974,049 3.113.291,778,209 3.28
$3.91 - $7.41226,222 3.164.63226,222 4.63
$7.42 - $40.00128,618 1.3020.80128,618 20.80
5,100,829 3.003.333,359,589 3.52

Option grants vest either immediately or annually over periods ranging from one to three years.

We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.



9

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
The estimated fair value of stock options granted during the period was determined using the following weighted average assumptions:
20222021
Risk-free interest rate1.17%0.49%
Expected hold period to exercise3.0 years3.0 years
Expected share price volatility115.43%110.78%
Expected dividend yieldNilNil
Weighted average fair value of options$1.17$2.26

Incentive Share Award Plan

Restricted Share Units ("RSUs")
We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three-year period. The following RSUs are outstanding at March 31:
20222021
Outstanding, beginning of the period40,560 134,618 
Released(18,266)(16,956)
Outstanding, end of the period22,294 117,662 

We have reserved 5,750,169 common shares for issuance relating to our outstanding equity compensation plans. Our share-based compensation was $638,981 for the three months ended March 31, 2022 (March 31, 2021 - $658,076).

Note 7: Loss Per Common Share
 
Loss per common share is calculated using net loss for the period and the weighted average number of common shares outstanding for the three months ended March 31, 2022 of 56,576,462 (March 31, 2021 - 49,666,585). The effect of any potential exercise of our stock options and warrants outstanding during the period has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.

Note 8: Commitments
 
We are committed to payments totaling $18,763,403 for activities mainly related to our clinical trial, manufacturing and translational science programs which are expected to occur over the next three years.

Our commitments include the committed payments related to our co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at March 31, 2022, we recorded US$1,847 ($2,308) (December 31, 2021 - US$616,855 ($782,049)) in other receivables related to BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and nil (December 31, 2021 - US$277,866 ($352,279)) in other liabilities representing future trial costs to be incurred.

Under a clinical trial agreement entered into with the Alberta Cancer Board (“ACB”), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product. We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.

10

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
Leases
Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable.
Our total undiscounted lease liability as at March 31, 2022 is as follows:
March 31,
2022
Less than one year$374,673 
One to five years337,943 
More than five years— 
Total undiscounted lease liability$712,616 


Note 9: Capital Disclosures
 
Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection. We include shareholders' equity and cash and cash equivalents in the definition of capital.
 March 31,
2022		December 31,
2021
Cash and cash equivalents$39,483,022 $41,262,044 
Shareholders’ equity$35,015,166 $36,098,985 

We do not have any debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.

In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year’s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.

Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required.

On June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.

Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential
11

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.

Our Base Shelf allowed us to enter into our ATM equity distribution agreement in March 2021 (see Note 5). We use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital and better manage our cash resources.

We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2022.

Note 10: Financial Instruments
 
Fair value of financial instruments

Our financial instruments consist of cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and warrant derivative. As at March 31, 2022, the carrying amount of our cash and cash equivalents, other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at March 31, 2022, the fair value of our warrant derivative was $68,231 (December 31, 2021 - $56,017). We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding.  

Financial risk management

Credit risk
Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.

We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.

Interest rate risk
Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.
 
Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.

Foreign exchange risk
Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $329,000. 

12

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.

Significant balances in foreign currencies at March 31, 2022 are as follows:

US dollars
Cash and cash equivalents$29,077,813 
Accounts payable and accrued liabilities(1,045,472)
$28,032,341 

Liquidity risk
Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 9. Accounts payable and accrued liabilities are all due within the current operating period.

Note 11: Additional Cash Flow Disclosures
 
Net Change In Non-Cash Working Capital
For the three months ended March 31,20222021
Change in:  
Other receivables$763,838 $(22,004)
Prepaid expenses(1,174,532)(454,530)
Accounts payable and accrued liabilities60,606 113,623 
Other liabilities(352,279)(123,985)
Non-cash impact of foreign exchange45,562 (109,583)
Change in non-cash working capital related to operating activities$(656,805)$(596,479)

Other Cash Flow Disclosures
For the three months ended March 31,20222021
Cash interest received$42,478 $35,302 

13

ONCOLYTICS BIOTECH INC.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in Canadian dollars, except share amounts)
March 31, 2022
Note 12: Other Expenses and Adjustments

The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange loss as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include expenses paid to third parties.
For the three months ended March 31,20222021
Research and development expenses:
Employee compensation and benefits$1,186,387 $918,180 
Share-based compensation359,316 361,603 
Operating expenses:
Depreciation - property and equipment$23,952 $20,550 
Depreciation - right-of-use-assets73,612 86,184 
Employee compensation and benefits574,230 531,587 
Share-based compensation279,665 296,473 

Note 13: Related Party Transactions

Compensation of Key Management Personnel
Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.
For the three months ended March 31,20222021
Short-term employee compensation and benefits$794,134 $784,631 
Share-based compensation451,915 459,293 
$1,246,049 $1,243,924 

14